vTv Therapeutics (VTVT) Accounts Payables (2014 - 2026)

vTv Therapeutics has disclosed Accounts Payables across 13 years of filings, most recently posting $6.8 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $6.8 million, up 62.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (up 62.75% YoY), and the FY2025 annual result was $6.6 million, up 30.44% from the prior year.
• Accounts Payables came in at $6.8 million for Q1 2026 at vTv Therapeutics, up from $6.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $12.5 million in Q1 2022 to a low of $4.2 million in Q1 2025.
• The 5-year median for Accounts Payables is $7.3 million (2022), against an average of $7.8 million.
• Across the five-year window, Accounts Payables soared 151.24% in 2022 and sank 52.0% in 2025, its largest moves.
• vTv Therapeutics' Accounts Payables stood at $7.3 million in 2022, then surged by 40.05% to $10.2 million in 2023, then sank by 50.92% to $5.0 million in 2024, then jumped by 30.44% to $6.6 million in 2025, then climbed by 4.03% to $6.8 million in 2026.
• The last three Accounts Payables figures came in at $6.8 million (Q1 2026), $6.6 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.